ES2153671T3 - Peptidos neuroactivos. - Google Patents

Peptidos neuroactivos.

Info

Publication number
ES2153671T3
ES2153671T3 ES97927691T ES97927691T ES2153671T3 ES 2153671 T3 ES2153671 T3 ES 2153671T3 ES 97927691 T ES97927691 T ES 97927691T ES 97927691 T ES97927691 T ES 97927691T ES 2153671 T3 ES2153671 T3 ES 2153671T3
Authority
ES
Spain
Prior art keywords
neuroactive peptides
specific identification
neuroactive
peptides
nmda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97927691T
Other languages
English (en)
Inventor
Joseph R Moskal
Hirotaka Yamamoto
Patricia A Colley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NYXIS Neuro Therapies Inc
Original Assignee
NYXIS Neuro Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NYXIS Neuro Therapies Inc filed Critical NYXIS Neuro Therapies Inc
Application granted granted Critical
Publication of ES2153671T3 publication Critical patent/ES2153671T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE DESCRIBEN COMPOSICIONES Y PROCEDIMIENTOS PARA LA IDENTIFICACION ESPECIFICA DE RECEPTORES DE NMDA, ASI COMO PARA LA IDENTIFICACION ESPECIFICA Y MANIPULACION DE LA ACTIVIDAD BIOLOGICA CO - AGONISTA DE LA GLICINA DEL NMDA.
ES97927691T 1996-05-17 1997-05-16 Peptidos neuroactivos. Expired - Lifetime ES2153671T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/649,272 US5763393A (en) 1996-05-17 1996-05-17 Neuroactive peptides

Publications (1)

Publication Number Publication Date
ES2153671T3 true ES2153671T3 (es) 2001-03-01

Family

ID=24604116

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97927691T Expired - Lifetime ES2153671T3 (es) 1996-05-17 1997-05-16 Peptidos neuroactivos.

Country Status (12)

Country Link
US (2) US5763393A (es)
EP (2) EP1077217A3 (es)
JP (1) JP2000501746A (es)
AT (1) ATE197307T1 (es)
AU (1) AU3209097A (es)
CA (1) CA2255659C (es)
DE (1) DE69703449T2 (es)
DK (1) DK0914331T3 (es)
ES (1) ES2153671T3 (es)
GR (1) GR3035227T3 (es)
PT (1) PT914331E (es)
WO (1) WO1997043306A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001271366A1 (en) * 2000-06-22 2002-01-02 Nyxis Neurotherapies, Inc. Neuroactive peptides for treatment of hypoxia and related conditions
WO2003010540A1 (en) * 2001-07-25 2003-02-06 Nyxis Neurotherapies, Inc. Method of identifying nmda-related agent
MX2011003015A (es) 2008-09-18 2011-11-18 Univ Northwestern Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos.
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
PL2485751T3 (pl) 2009-10-05 2014-10-31 Univ Northwestern GLYX-13 do stosowania w sposobie leczenia depresji opornej na leczenie
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
CN105037492A (zh) 2010-02-11 2015-11-11 西北大学 二级结构稳定化的nmda受体调节剂及其用途
US20140107037A1 (en) 2011-04-27 2014-04-17 Northwestern University Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders
US8798716B1 (en) 2011-11-03 2014-08-05 Solstice Corporation Fiducial markers and related methods
US8974365B2 (en) 2012-11-25 2015-03-10 Steven Richard Devore Best Treatment of thalamocortical dysrhythmia
EP4385563A3 (en) 2013-01-22 2024-08-21 Vistagen Therapeutics, Inc. Dosage forms and therapeutic uses l-4-chlorokynurenine
SG11201505862TA (en) 2013-01-29 2015-08-28 Naurex Inc Spiro-lactam nmda receptor modulators and uses thereof
EA032649B1 (ru) 2013-01-29 2019-06-28 Аптиникс Инк. Спиролактамные модуляторы nmda-рецептора и их применение
KR20150110787A (ko) 2013-01-29 2015-10-02 노렉스, 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
SG11201505942YA (en) 2013-01-29 2015-08-28 Naurex Inc Spiro-lactam nmda receptor modulators and uses thereof
KR20150110586A (ko) 2013-01-29 2015-10-02 노렉스, 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
GB201319437D0 (en) * 2013-11-04 2013-12-18 Nanomerics Ltd Delivery of drugs
EP3134103B1 (en) 2014-04-25 2020-01-15 Naurex Inc. Stable compositions of neuroactive peptides
WO2016014982A1 (en) * 2014-07-24 2016-01-28 Naurex, Inc. N-methyl-d-aspartate receptor modulators and methods of making and using same
RU2017107033A (ru) 2014-08-14 2018-09-14 Наурекс, Инк. Способы лечения депрессии с применением модуляторов nmda
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
BR112018073663A2 (pt) 2016-05-19 2019-04-30 Aptinyx Inc. moduladores de receptores nmda spiro-lactâmicos e seus usos
MX385336B (es) 2016-08-01 2025-03-18 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos.
SG10202101055VA (en) 2016-08-01 2021-03-30 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
JP2019527232A (ja) 2016-08-01 2019-09-26 アプティニックス インコーポレイテッド スピロ−ラクタムｎｍｄａ修飾因子及びこれを用いた方法
WO2018026782A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
EP3490994B8 (en) 2016-08-01 2024-03-13 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
JP2021512857A (ja) 2017-11-10 2021-05-20 ノーレックス インコーポレイテッド Ｎｍｄａ受容体アゴニストの投与方法
CA3084437A1 (en) 2017-12-05 2019-06-13 Naurex Inc. Nmda receptor modulators (rapastinel) combination for use in combined treatment (sleep and cns disorder)
CN112204031B (zh) 2018-01-31 2024-05-24 元羿生物科技(香港)有限公司 螺-内酰胺nmda受体调节剂及其用途
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854217A (en) * 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
US5428069A (en) * 1993-01-11 1995-06-27 The United States Of America As Represented By The Department Of Health & Human Services Treating cognition with, aminocyclopropanecarboxylic derivatives
JPH07101999A (ja) * 1993-10-06 1995-04-18 Hagiwara Yoshihide 抗癌ヒトモノクローナル抗体に対する抗イデイオタイプ抗体のアミノ酸配列およびそれをコードするｄｎａ塩基配列

Also Published As

Publication number Publication date
AU3209097A (en) 1997-12-05
CA2255659C (en) 2005-03-15
DE69703449D1 (de) 2000-12-07
WO1997043306A1 (en) 1997-11-20
EP0914331B1 (en) 2000-11-02
ATE197307T1 (de) 2000-11-15
GR3035227T3 (en) 2001-04-30
DE69703449T2 (de) 2001-06-07
DK0914331T3 (da) 2001-02-12
CA2255659A1 (en) 1997-11-20
EP1077217A3 (en) 2004-01-02
US6107271A (en) 2000-08-22
PT914331E (pt) 2001-04-30
US5763393A (en) 1998-06-09
EP0914331A1 (en) 1999-05-12
EP1077217A2 (en) 2001-02-21
JP2000501746A (ja) 2000-02-15

Similar Documents

Publication Publication Date Title
ES2153671T3 (es) Peptidos neuroactivos.
DE59710609D1 (de) Mittel zur Herstellung von Leder
ITTO950367A0 (it) Proteine di prrsv ricombinanti, corredi diagnostici e vaccini contenenti tali proteine di prrsv ricombinanti.
BR0009206A (pt) Isolamento e análise de proteina
FI963461A0 (fi) Häiriönpoistoaineet immunologisia määrityksiä varten
DE69739219D1 (de) Peptide und zusammensetzungen, die an den thrombopoietin-rezeptor binden
DE69737948D1 (de) Vorrichtung zur rekonstruktion von sehnen
EP0918787A4 (en) COMPOSITIONS AND METHODS FOR ANTISENSE INHIBITION OF PROTEIN TRANSLATION
NO984644L (no) Ikke-dendrittisk ryggradpeptidbµrer
DE69834759D1 (de) Vorrichtung für den Empfang von Rundfunkprogrammen
NO921256D0 (no) Aminosyre-beta-lyaseenzyminhibitor som deodoranter
BR9812490A (pt) Sistema de reconhecimento modular endereçável, sua preparacão e uso
WO1999020747A3 (en) HUMAN CHECKPOINT KINASE, hCDS1, COMPOSITIONS AND METHODS
DE69634489D1 (de) Adenovirus dodekahedrischer proteinkomplex, dieser enthaltende zusammensetzung und verwendungen davon
DE69811183D1 (de) Vorrichtung zur Trocknung von Druckgas
DE59711900D1 (de) Vorrichtung zur kuppelprojektion
GB9816514D0 (en) Novel method
DE69939833D1 (de) Neues tumor-antigen-protein sart-3 und tumor-antigen-peptid davon
EP0749320A4 (en) FIBRIN-SPECIFIC ANTIBODIES FOR USE AS ANTITHROMBOSE AGENT
DE69738638D1 (de) System zum testen von echtzeit/netzunabhängigen anwendungen
PT929299E (pt) 1,2,3,4-tetra-hidro-2-dibenzofuranaminas e 2-aminociclo-hepta ¬b| benzofuranos substituidos
DE59711564D1 (de) Wiederlösbare, selbstklebende Vorrichtung
ATE385805T1 (de) Neue peptide
AU2172597A (en) Protein phosphatase-1 catalytic subunit interactions
DE69821053T2 (de) Verfahren zur Herstellung von 2,2,6,6-Tetramethyl-4-piperidyl-Gruppen enthaltenden Polytriazinen

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 914331

Country of ref document: ES